A method of individually releasing from an entity one or more members of a sub-group of biological units included in a heterogeneous group of biological units is provided. The method includes binding the group of biological units including the sub-group of biological units to the entity via a linker. Following binding, the location of the one or more members on the entity is determined. Once the location is determined, a localized physical pulse is applied to the one or more members. The localized physical pulse individually releases the one or more members from the entity by dissociating the linker.

Provided are methods for isolating subpopulations of stem cells. In some embodiments, the presently disclosed methods include selecting subsets of cells that are positive for CD34 or Sca-1, are further positive for one or more of FSHR, LHCGR, PRLR, AR, ESR, ESR, and PGR; and are negative for each of CD45R/B220, Gr-1, TCR, TCR, CD11b, and Ter-119. In some embodiments, the subpopulations are further fractioning into CD45.sup. and CD45.sup.+ fractions. Also provided are populations of stem cells isolated by the presently disclosed methods, compositions that include the presently disclosed subpopulations in pharmaceutically acceptable carriers, methods for expanding stem cells, methods for stimulating proliferation of MSCs, methods for treating subjects suffering from exposure to radiation, and methods for producing gametes in vitro.

This invention provides methods for determining or predicting response to cancer therapy in an individual using differential image analysis of immunohistochemically stained tumor samples.

The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently OH, OP(O)(OH)2 or P(O)(OH)2, with the proviso that at least two R are independently selected from P(O)(OH)2 and OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.

Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.

Provided herein are methods of determining the aggressiveness or indolence of a ductal carcinoma in situ lesion. Also provided are methods of development treatment plans for subjects with a ductal carcinoma in situ lesion based on the aggressiveness of the lesion.

A method of generating a population of corneal epithelial cells is disclosed. The method comprises culturing human pluripotent stem cells in corneal fibroblast-conditioned medium on a solid surface comprising an extracellular matrix component thereby generating the population of corneal epithelial cells. Isolated cell populations and corneal tissues are also disclosed, as well as uses thereof.

Methods for the detection of, or the risk of, bladder cancer in a patient, comprising assaying for the presence of a combination of at least two biomarkers selected from CEA, VEGF, IL-8, NGAL, NSE, IL-2, EGF, TM, d-Dimer, MMP-9, IL-6, IL-4, MMP-9/NGAL, FAS, CRP, TUP and NMP22 in one or more samples isolated from a patient wherein detecting the presence of a combination of at least two biomarkers in the one or more samples indicates the presence or risk of bladder cancer.